 Delcath Systems is moving closer to submitting their NDA for their drugdevice kit of melphalan hydrochloride with hepatic delivery system, HEPZATO. If approved, Delcath would have several. HEPZATO has produced some impressive data that shows it outperforming most of the contemporary therapies in metastatic ocular melanoma. 